BioLineRx Ltd.

BioLineRx Ltd., a clinical-stage biopharma company focused on oncology and rare diseases, reported FY 2025 revenues of $1.2 million, a 96% decline from $28.9 million in FY 2024, primarily due to the November 2024 out-licensing of motixafortide rights to Ayrmid (excluding Asia and solid tumors) and shutdown of U.S. commercialization. Revenues in 2025 consisted solely of $1.2 million in royalties from Ayrmid on APHEXDA (motixafortide) sales for stem cell mobilization. Net loss narrowed to $2.0 million from $9.2 million YoY, driven by reduced operating expenses post-commercial wind-down (R&D $8.1M vs $9.2M; no sales/marketing vs $23.6M) and $8.1M non-operating income from warrant fair value changes. Total assets stood at $40.9M, with cash/cash equivalents/short-term deposits at $20.9M ($3.2M cash + $17.6M deposits), supporting operations into H1 2027. Cash burn eased: operating -$8.1M (vs -$43.9M), investing -$8.5M, financing +$8.9M. Equity rose to $23.3M, liabilities fell to $17.6M. Forward-looking, focus shifts to GLIX1 development via Tetragon (40% owned) and motixafortide solid tumors (PDAC Phase 2b ongoing). Management highlights reduced burn rate and potential milestones/royalties from partnerships.

Key Takeaways